Durvalumab plus enfortumab vedotin before surgery improves survival in bladder cancer

A phase 3 trial has found that adding durvalumab and enfortumab vedotin around bladder removal surgery improves outcomes for people with muscle-invasive bladder cancer who cannot, or will not, take cisplatin chemotherapy. Compared with surgery alone, the two-drug regimen was associated with a 42% lower risk of death…